Christian Schweiger
Vermögen: 619 405 $ am 31.07.2026
Vermögen: 619 405 $ am 31.07.2026
Christian Schweiger was the founder of Shield Holdings AG, founded in 2008, where the title held was Chief Medical Officer from 2013 to 2015.
Dr. Schweiger is the founder of Shield Therapeutics Plc, founded in 2008, holding the title of Non-Executive Director since 2020.
Current jobs include Chairman at Arxx Therapeutics AS since 2021, Non-Executive Director at AOP Orphan International AG since 2021, Professor at the University of Duisburg-Essen, and President at Tachris AG.
Former jobs include Senior Director at Encysive Pharmaceuticals, Inc., Principal at Actelion Ltd., Principal at Sandoz AG, Principal at Aventis Bio-Services, Inc., and Principal at Thelin Hearth Products, Inc. Education includes a doctorate from the University of Hamburg.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2025 | 11’651’713 ( 1.09% ) | 619 405 $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SHIELD THERAPEUTICS PLC | Gründer | 01.01.2008 |
University of Duisburg-Essen
University of Duisburg-Essen Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Tachris AG | Präsident | - |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Develops therapeutics for fibrotic diseases | Vorsitzender | 01.11.2021 |
AOP Orphan International AG | Direktor/Vorstandsmitglied | 01.10.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Develops generic medicines and biosimilars | Corporate Officer/Principal | - |
Thelin Hearth Products, Inc..
Thelin Hearth Products, Inc.. Building ProductsProducer Manufacturing Manufactures wood, pellet and gas stoves | Corporate Officer/Principal | - |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases | Direktor/Vorstandsmitglied | - |
| ACTELION | Direktor/Vorstandsmitglied | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases | Health Technology |
Actelion Ltd.
Actelion Ltd. Pharmaceuticals: MajorHealth Technology Develops, produces and markets pharmaceutical drugs | Health Technology |
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Develops generic medicines and biosimilars | Health Technology |
Aventis Bio-Services, Inc.
Aventis Bio-Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical and agricultural products | Health Technology |
University of Hamburg
University of Hamburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Duisburg-Essen
University of Duisburg-Essen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thelin Hearth Products, Inc..
Thelin Hearth Products, Inc.. Building ProductsProducer Manufacturing Manufactures wood, pellet and gas stoves | Producer Manufacturing |
Shield Holdings AG
Shield Holdings AG Pharmaceuticals: MajorHealth Technology Develops and commercializes late stage pharma products | Health Technology |
Shield Therapeutics Plc
Shield Therapeutics Plc Pharmaceuticals: MajorHealth Technology Develops and commercializes late stage pharmaceutical products | Health Technology |
Tachris AG | |
AOP Orphan International AG | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Develops therapeutics for fibrotic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen